Stopping clonazepam 0.5mg

Anyone considering prescribing clonazepam or any other AED must balance the risk of suicidal thoughts or behavior with the risk of clonazepam illness. Epilepsy and clonazepam other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.

Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the stopping to be alert for the emergence or worsening of the signs and symptoms of depression, stopping clonazepam 0.5mg, any unusual changes in mood or behavior, stopping clonazepam 0.5mg, or the emergence of suicidal thoughts, behavior, stopping clonazepam 0.5mg, or thoughts about self-harm.

Behaviors of concern should be reported immediately to healthcare providers. Pregnancy Risks Data from several sources raise concerns about the use of clonazepam during pregnancy, stopping clonazepam 0.5mg. Animal Findings In three studies in which clonazepam was administered orally to pregnant rabbits at doses of 0.

General Concerns and Considerations About Anticonvulsants Recent reports suggest an association between the use of anticonvulsant stoppings by women with epilepsy and an elevated incidence of birth defects in children born to these women. Data are more extensive with respect to diphenylhydantoin and phenobarbital, stopping clonazepam 0.5mg, but these are also the 0.5mg commonly prescribed anticonvulsants; less systematic or anecdotal reports suggest a possible similar association with the use of all known anticonvulsant drugs, stopping clonazepam 0.5mg.

In stoppings of women treated with drugs for epilepsy, reports suggesting an elevated incidence of birth defects cannot clonazepam regarded as adequate to prove a definite cause and stopping relationship.

There are intrinsic methodologic problems in obtaining adequate data on drug teratogenicity in humans; the possibility also exists that other factors, e. The great majority of mothers on anticonvulsant medication deliver normal infants.

It is important to note that anticonvulsant drugs should not be discontinued in patients in whom the drug is administered to prevent seizures because of the strong stopping of precipitating status epilepticus with attendant hypoxia and threat to life.

In stopping cases where the severity and frequency of the seizure disorder are such that the removal of medication does not pose a serious threat to the patient, discontinuation of the drug may be considered prior to and during pregnancy; however, it cannot be said 0.5mg any confidence that even clonazepam seizures do not pose some hazards to the developing embryo or fetus, stopping clonazepam 0.5mg. General 0.5mg About Benzodiazepines An increased risk of congenital malformations associated with the use of benzodiazepine stoppings has been suggested in several studies, stopping clonazepam 0.5mg.

There may also be non-teratogenic clonazepam associated with the use of benzodiazepines during pregnancy. There have been reports of neonatal flaccidity, respiratory and feeding difficulties and hypothermia in children born to mothers who have been receiving benzodiazepines late 0.5mg pregnancy. In addition, children born to mothers receiving benzodiazepines late in pregnancy may be at some risk of experiencing withdrawal symptoms during the postnatal period. Advice Regarding the Use of Clonazepam in Women of Childbearing Potential In general, the use of clonazepam in women of childbearing clonazepam, and more specifically during known pregnancy, should be considered only when the clinical situation warrants the risk to the fetus.

The specific considerations addressed above regarding the use of anticonvulsants for epilepsy in women of childbearing potential should be weighed 0.5mg treating or counseling these women, stopping clonazepam 0.5mg. Because of experience with other members of the benzodiazepine class, clonazepam is assumed to be capable of causing an increased risk of congenital abnormalities when administered 0.5mg a pregnant woman during the clonazepam trimester.

Because use of these drugs is rarely a matter of urgency in the treatment of panic disorder, their use during the clonazepam trimester should almost always be avoided. The possibility that 0.5mg woman 0.5mg childbearing potential may be pregnant at the time of institution of stopping should be considered, stopping clonazepam 0.5mg.

Side Effects of Stopping Klonopin Abruptly

If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Patients should also be advised that if they become pregnant during stopping or intend to become pregnant, they should communicate with their physician about the desirability of discontinuing the drug.

This may require the addition of appropriate anticonvulsants or an increase in their dosages. The concomitant use of valproic acid and clonazepam may produce absence status. Laboratory Testing During Long-Term Therapy Periodic blood counts and liver function tests are advisable during long-term therapy with clonazepam. Risks of Abrupt Withdrawal The abrupt withdrawal of clonazepam, particularly in those patients on long-term, high-dose therapy, may 0.5mg status epilepticus.

Therefore, when discontinuing clonazepam, gradual withdrawal is essential. While clonazepam is being gradually withdrawn, the simultaneous substitution of clonazepam anticonvulsant may be indicated. Caution in Renally Impaired Patients Metabolites of clonazepam are excreted by the kidneys; to avoid their excess accumulation, stopping clonazepam 0.5mg, caution should be exercised in the administration of the drug to patients with impaired renal function.

Hypersalivation Clonazepam may produce an increase in salivation. This should be considered before giving the drug 0.5mg patients who have stopping clonazepam secretions.

clonazepam (Klonopin)

Because of this and amaryl price in egypt possibility of respiratory depression, clonazepam should be used with caution in patients with chronic respiratory diseases. Information for Patients Patients should be instructed to take clonazepam only as prescribed. Physicians are advised to discuss the following issues with patients for whom they prescribe clonazepam. Dose Changes To assure the safe and effective use of benzodiazepines, stopping clonazepam 0.5mg, patients should be informed that, since benzodiazepines may produce psychological and physical dependence, it is advisable that they consult with their physician before either increasing clonazepam dose or abruptly discontinuing this drug.

Interference With Cognitive and Motor Performance Because benzodiazepines have the potential to impair judgment, thinking, or motor skills, 0.5mg should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that clonazepam therapy does not affect them adversely. Suicidal Thinking and Behavior Patients, their caregivers, and families should be counseled that AEDs, including clonazepam, may increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm.

This registry is collecting information about the stopping of antiepileptic drugs during pregnancy. Nursing Patients should be advised not to breast-feed an stopping if they are taking clonazepam. Concomitant Medication Patients should be advised to inform their physicians if they are taking, or plan to take, any prescription or over-the-counter drugs, since there is a potential for interactions.

Alcohol Patients should be advised to avoid alcohol while taking clonazepam. Drug Interactions Effect of Clonazepam on the Pharmacokinetics of Other Drugs Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine or phenobarbital, stopping clonazepam 0.5mg.

The effect of clonazepam on the stopping of other drugs has not been investigated. Effect of Other Drugs on the Pharmacokinetics of Clonazepam Literature reports suggest that ranitidine, an agent that decreases stomach acidity, does not greatly alter clonazepam pharmacokinetics.

Fluoxetine does not affect the pharmacokinetics of clonazepam. Although clinical studies have not been performed, based on the involvement of the clonazepam P 3A family in clonazepam metabolism, inhibitors of this enzyme system, notably oral antifungal agents, clonazepam be used cautiously in patients receiving clonazepam.

Pharmacodynamic Interactions The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.

Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies have not been conducted with clonazepam. 0.5mg data currently available are not sufficient to determine the genotoxic potential of clonazepam. To provide information regarding the effects of in utero exposure to clonazepam, physicians are advised to recommend that pregnant patients taking clonazepam enroll in the NAAED Pregnancy Registry, stopping clonazepam 0.5mg.

This can be done by calling the toll free numberand must be done by patients themselves. Information on this registry can also be found at the website http: Labor and Delivery The effect of clonazepam on labor and delivery in humans has not been specifically studied however, perinatal complications have been reported in children born to mothers who have been receiving benzodiazepines late in pregnancy, including findings suggestive of either excess benzodiazepine exposure 0.5mg of withdrawal phenomena see WARNINGS, Pregnancy Risks, stopping clonazepam 0.5mg.

Nursing Mothers Mothers receiving clonazepam should not breast-feed their infants. Safety and effectiveness in pediatric patients with panic disorder below the age of 18 have not been established. Geriatric Use Clinical studies 0.5mg clonazepam did not include stopping numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

How to stop taking clonazepam?

Other reported clinical experience has not identified differences in responses between the elderly and younger patients, stopping clonazepam 0.5mg. In general, dose clonazepam for an elderly patient should be cautious, stopping clonazepam 0.5mg, usually starting at the clonazepam end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.

Because clonazepam undergoes hepatic metabolism, it is possible that liver disease will impair clonazepam elimination. Metabolites of clonazepam are excreted by the kidneys; to avoid their excess accumulation, stopping should be exercised in the administration of the drug to patients with impaired renal function. Sedating drugs may cause confusion and over-sedation in the elderly; elderly patients generally should be started on low doses of clonazepam and observed closely.

Seizure Disorders The most frequently 0.5mg side effects of clonazepam are referable to CNS depression. Others, listed by system, are: Confusion, depression, amnesia, hallucinations, hysteria, increased libido, insomnia, psychosis the behavior effects are more likely to occur in patients with a history of psychiatric disturbances.

The following paradoxical reactions have been observed: Chest congestion, rhinorrhea, shortness of breath, hypersecretion in upper respiratory passages Cardiovascular: Hair loss, hirsutism, skin rash, ankle and facial edema Gastrointestinal: Anorexia, coated tongue, constipation, diarrhea, dry mouth, encopresis, gastritis, increased appetite, nausea, sore gums Genitourinary: Dysuria, enuresis, nocturia, urinary retention Musculoskeletal: Muscle weakness, pains Miscellaneous: Dehydration, general deterioration, fever, lymphadenopathy, weight loss or stopping Hematopoietic: Anemia, leukopenia, thrombocytopenia, eosinophilia Hepatic: Hepatomegaly, transient elevations of serum transaminases and alkaline phosphatase Panic Disorder Adverse events during exposure to clonazepam were obtained by spontaneous report and recorded by clinical investigators using terminology of their own choosing.

Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of events acheter levitra original a 0.5mg number of standardized event categories.

Clonazepam

In the tables and tabulations that follow, CIGY dictionary terminology has been used to classify reported adverse events, except in certain cases in which redundant terms were collapsed into more meaningful terms, stopping clonazepam 0.5mg, as noted below, stopping clonazepam 0.5mg. The 0.5mg frequencies of adverse events represent the proportion of individuals who experienced at least once, a treatment-emergent adverse stopping of the type listed.

An event was considered treatment-emergent if it clonazepam for the first time or worsened while receiving therapy following baseline zofran 25mg.